Accessibility Menu
Plus Therapeutics logo

Plus Therapeutics(NASDAQ) PSTV

Current Price$3.82
Market Cap$26.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-100%
5 Year-100%
1 Year-64%
1 Month-4%
Plus Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 3.822026-07-22
Plus Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.37%USD 4.082026-07-15
1 month-4.02%USD 3.982026-06-22
3 month-47.53%USD 7.282026-04-23
Year to date-70.17%USD 12.812025-12-31
1 year-64.05%USD 10.632025-07-22
3 year-92.89%USD 53.752023-07-21
5 year-99.52%USD 802.502021-07-23
Since inception-100%USD 10,404,949.382003-07-01

Plus Therapeutics Financials at a Glance

Market Cap

$26.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$5.18M

Net Income (TTM)

-$11.93M

EPS (TTM)

-$3.27

P/E Ratio

-1.17

Dividend

$0.00

Beta (Volatility)

1.14 (Average)

Price

$3.82

Volume

57,632

Open

$3.90

Previous Close

$3.82

Daily Range

$3.77 - $3.93

52-Week Range

$2.90 - $23.43

Estimated Earnings Date

Aug 13, 2026

PSTV News

Foolcom-Featured.png

Plus Therapeutics Posts Q2 Profit Jump

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Plus Therapeutics

Plus Therapeutics, Inc. is a U.S.-based pharmaceutical company dedicated to developing targeted radiotherapeutics for central nervous system cancers. With innovative technologies, they focus on delivering radiation directly to tumors, aiming to reduce damage to healthy tissues. This approach could revolutionize treatment for rare and challenging cancer types.

Products and Services

Rhenium-186 obisbemeda: A radiotherapeutic designed for CNS cancers delivered directly to tumor sites.

Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere: Targeted treatment for solid organ cancers like liver cancer.

Research and development in radiotherapeutic technologies.

What Makes Plus Therapeutics, Inc. Special

Plus Therapeutics leverages its proprietary nanoliposome technology to deliver radiotherapeutic agents precisely, potentially improving efficacy and minimizing damage to healthy tissues. This sets them apart by addressing unmet needs in rare and difficult-to-treat cancer markets.

Five Things You Need to Know

Focus on treating rare cancers with significant unmet medical needs.

Leading product, Rhenium-186 obisbemeda, is in advanced clinical trials for various CNS cancers.

Strong strategic partnerships enhance supply chain and development capabilities.

Headquartered in Texas, near major cancer research institutions.

Uses a patented platform technology with potential applications beyond current cancer targets.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

28

CEO

Marc H. Hedrick, MD, MBA

Website

www.plustherapeutics.com

Headquarters

Austin, TX 78756, US

PSTV Financials

Key Financial Metrics (TTM)

Gross Margin

92.80%

Operating Margin

-364.36%

Net Income Margin

-230.24%

Return on Equity

-198.48%

Return on Capital

-317.58%

Return on Assets

-59.91%

Earnings Yield

-85.47%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$26.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

6.88M

Volume

57.63K

Avg. Volume

172.22K

Financials (TTM)

Gross Profit

$4.81M

Operating Income

-$18.88M

EBITDA

-$8.21M

Operating Cash Flow

-$20.84M

Capital Expenditure

-$882.00K

Free Cash Flow

-$21.72M

Cash & ST Invst.

$3.02M

Total Debt

$725.00K

Plus Therapeutics Performance Analysis

Plus Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 224,000N/A
20232023-12-31USD 4,913,0002093.3%
20242024-12-31USD 5,824,00018.5%
20252025-12-31USD 5,213,000-10.5%
Plus Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3031.3%
Q32025-09-300.5%
Q42025-12-31-2.1%
Q12026-03-31-24.8%
Plus Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -289.59-30.3%
20232023-12-31USD -105.99-63.4%
20242024-12-31USD -58.52-44.8%
20252025-12-31USD -7.19-87.7%
Plus Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3099.5%
Q32025-09-3099.4%
Q42025-12-31-3.0%
Q12026-03-31-1.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$1.03M

-2.9%

Gross Profit

$919.00K

+4.7%

Gross Margin

89.40%

N/A

Market Cap

$26.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$939.05K

N/A

Employees

28

N/A

Net Income

-$6.95M

+60.1%

EBITDA

-$6.82M

+49.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$3.02M

-69.4%

Total Debt

$725.00K

+1712.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$725.00K

+1712.5%

Return on Assets

-59.91%

N/A

Return on Invested Capital

-1.58%

N/A

Free Cash Flow

-$7.06M

-14.3%

Operating Cash Flow

-$6.24M

-1.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PLURPluri Inc.
$1.85-5.13%
JSPRJasper Therapeutics, Inc.
$0.74-3.27%
TAOXTAO Synergies Inc.
$3.67+0.27%
NXTCNextCure, Inc.
$4.40-13.89%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$23.04+0.04%
ONDSOndas
$8.00+0.04%
AALAmerican Airlines Group
$14.79-0.03%
PATHUiPath
$10.70-0.11%

Questions About PSTV

What is the current price of Plus Therapeutics?

Plus Therapeutics is trading at $3.82 per share.

What is the 52-week range for Plus Therapeutics?

Over the past 52 weeks, Plus Therapeutics has traded between $2.90 and $23.43.

How much debt does Plus Therapeutics have?

As of the most recent reporting period, Plus Therapeutics reported total debt of $725.00K.

How much cash does Plus Therapeutics have on hand?

Plus Therapeutics reported $3.02M in cash and cash equivalents in its most recent financial results.

What is Plus Therapeutics’s dividend yield?

Plus Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services